GlassScriptPhysician profile
Robert Billingsley
NPI 1538798038
$1,326.95
in general payments reported to CMS, 2019-2025
15 companies · $999 in 2025
The $999 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $328 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.41 | 2024-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $169.72 | 2025 | Evkeeza |
| Novo Nordisk INC | $153.35 | 2024-2025 | Wegovy |
| Philips North America LLC | $131.00 | 2025 | Lm Undivided |
| Abiomed | $122.43 | 2025 | |
| Penumbra, INC. | $118.33 | 2025 | Indigo System |
| Pfizer INC. | $100.40 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $71.61 | 2025 | Verquvo |
| Bridgebio Pharma, INC. | $66.61 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $55.35 | 2025 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $51.11 | 2024-2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $27.39 | 2025 | Amvuttra |
| Boston Scientific Corporation | $21.97 | 2024 | Latitude Communicator Power Supply |
| Edwards Lifesciences Corporation | $20.14 | 2024 | Sapien 3 Ultra Resilia |
| Stryker Corporation | $16.13 | 2025 | Artix Mt, Flowtriever, Clottriever Bold Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Billingsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.